www.enyopharma.com Open in urlscan Pro
185.116.176.98  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.enyopharma.com/

<form role="search" method="get" class="form-horizontal" action="https://www.enyopharma.com/">
  <div class="form-group" style="margin-bottom: 0;">
    <div class="input-group">
      <span class="input-group-addon">
        <span class="glyphicon glyphicon-search" aria-hidden="true"></span>
      </span>
      <input type="search" class="form-control" placeholder="Search for…" value="" name="s" title="Search for:">
    </div>
  </div>
  <input type="hidden" name="lang" value="en">
</form>

Text Content

Toggle navigation
 * About us
   * Company overview
   * Founders
   * Management
   * Board
   * Investors
 * Technology
   * An innovative approach
   * Interactome datasets
   * Unique tools
   * Broad applications
   * Publications / Posters
 * Pipeline
   * R&D Pipeline
   * Vonafexor (EYP001) in HBV
   * Vonafexor (EYP001) in NASH
   * EYP002
   * Early Programs
 * Partnerships
   * Private partnerships
   * Public Collaborations
   * Consortiums
 * News
   * Latest news
   * Press releases
   * Events
   * Media coverage
 * Contact
   * How to find us
   * Careers
   * Legal Information
   * LinkedIn
 * 
 * 
 * 
 * 

 
 

 


BIOMIMETISM TO DISCOVER AND DEVELOP NEW DRUGS

ENYO Pharma is a clinical stage Biotech with a unique drug discovery platform
inspired by viruses.

The company is conducting three Phase 2 with its lead compound Vonafexor
(EYP001, a non-Bile Acid FXR agonist) in Chronic Hepatitis B and in NASH.

Several additional innovative drug discovery programs are progressing speedily
towards non-Clinical Development; their human targets being yet untapped by
Pharma’s, these programs can moreover be developed for various indications
(metabolic diseases, oncology…).

LATEST PRESS RELEASE



ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver
Meeting.
Lyon, France. November 3rd, 2021 - ENYO Pharma (ENYO), a private clinical ...

> Read more

EXECUTIVE TEAM



ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership
and scientific excellence in biology and drug development to bring the company
forward.

> Read more

PIPELINE



ENYO Pharma’s discovery engine has already nurtured key programs: a phase I
clinical trial ongoing for chronic hepatitis B, a phase II planned for NASH and
other programs for various indications (of which one funded by EU)

> Read more

NEXT EVENT



.


> Read more

 * About us
   * Company overview
   * Founders
   * Management
   * Board
   * Investors
 * Technology
   * An innovative approach
   * Interactome datasets
   * Unique tools
   * Broad applications
   * Publications / Posters
 * Pipeline
   * R&D Pipeline
   * Vonafexor (EYP001) in HBV
   * Vonafexor (EYP001) in NASH
   * EYP002
   * Early Programs
 * Partnerships
   * Private partnerships
   * Public Collaborations
   * Consortiums
 * News
   * Latest news
   * Press releases
   * Events
   * Media coverage
 * Contact
   * How to find us
   * Careers
   * Legal Information
   * LinkedIn

© 2020 ENYO Pharma SA